Results - Announcements
Glaxosmithkline Pharmaceuticals Ltd share price gained 1.78% to Rs 2573.3 after the company's net profit jumped 41.61% to Rs 335.88 crore, while revenue from operations increased sharply by 26.12% to Rs 1183.57 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 5.29%. It has improved by 2.69% over last one week and ticked higher by 1.38% in last one month while the market capitalization of Glaxosmithkline Pharmaceuticals Ltd has marginally improved by 3.40% and 0.26% in the same period respectively.
Profit before tax (PBT) of Glaxosmithkline Pharmaceuticals Ltd stood at Rs 459.34 crore in Q3 FY26, surging by 29.76% year-on-year, and expanding by 42.45% quarter-on-quarter. EBITDA came in at Rs 329 crore, gaining 8.98% YoY and rallying 30.81% sequentially.
Total expenses jumped by 20.91% to Rs 796.52 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 128.92 crore, witnessing a sharp rise of 76.72% YoY, while employee benefits expense was at Rs 170.19 crore, rising by 7.01% YoY.
For the TTM ended FY26, revenue from operations grew marginally by 1.93% to Rs 3821.67 crore, while net profit rose by 11.69% to Rs 1035.98 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 103008% to Rs 1163.84 crore, and PBT expanded by 11.60% to Rs 1406.01 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 903.3 crore in FY26, as against Rs 1289.91 crore in FY25.
Glaxosmithkline Pharmaceuticals Ltd fell 5.85% in last one year, outperforming the benchmark BSE Sensex which has softened by 9.87% during the same period.